Exelixis, Inc.(NASDAQ:EXEL) on Mar. 25 announced that the Independent Data Monitoring Committee (IDMC) notified the company that a planned interim analysis of the COMET-1 phase 3 pivotal trial has been completed, and that the IDMC recommended the trial proceed to its final analysis. Exelixis continues to anticipate top-line data from COMET-1 in 2014. COMET-1 is a randomized, double-blind, controlled trial designed to enroll 960 patients with mCRPC who have progressed after treatment with docetaxel, abiraterone and/or enzalutamide. All patients in the trial have bone metastases and there is no limit to the number or type of prior treatments. Exelixis, Inc. (NASDAQ:EXEL), shares after opening at $3.34 moved to $3.35 on last trade day and at the end of the day closed at $3.22. Company price to sales ratio in past twelve months was calculated as 20.02 and price to cash ratio as 2.46. Exelixis, Inc. (NASDAQ:EXEL), showed a negative weekly performance of -13.67%.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) declared positive results in a clinical trial of type 1 diabetes drug LX4211. The trial discovered that the drug effectively lowered insulin use and enhanced glycemic control in patients with badly controlled diabetes.Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), shares sustain 0.00% in last trading session and ended the day on $1.55. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), return on equity ratio is recorded as -51.30% and its return on assets is -33.50%. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), yearly performance is -28.57%.
On April 1, 2014, Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), and Centre for Probe Development and Commercialization (CPDC) announced that Azedra™, a novel targeted radiotherapy candidate resuming phase 2 registrational testing in patients suffering from pheochromocytoma and paraganglioma, will be manufactured by CPDC for the developer of the compound, Progenics Pharmaceuticals. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), shares moved down 3.68% in last trading session and was closed at $3.40, while trading in range of $ 3.20 – 3.60. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), year to date (YTD) performance is -36.21%.
Cleveland BioLabs (NASDAQ:CBLI) reported ($0.01) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.12) by $0.11, Stock Ratings Network.com reports. The company had revenue of $3.87 million for the quarter, compared to the consensus estimate of $1.74 million. Cleveland BioLabs, Inc. (NASDAQ:CBLI), weekly performance is -14.29%. On last trading day company shares ended up $0.600. Cleveland BioLabs, Inc. (NASDAQ:CBLI), distance from 50-day simple moving average (SMA50) is -14.87%. Analysts mean target Price for the company is $2.00.
Leave a Reply